These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36263608)

  • 21. Bone Matrix Mineralization and Response to Burosumab in Adult Patients With X-Linked Hypophosphatemia: Results From the Phase 3, Single-Arm International Trial.
    Fratzl-Zelman N; Hartmann MA; Gamsjaeger S; Rokidi S; Paschalis EP; Blouin S; Zwerina J
    J Bone Miner Res; 2022 Sep; 37(9):1665-1678. PubMed ID: 35775373
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Burosumab for Pediatric X-Linked Hypophosphatemia.
    Imel EA
    Curr Osteoporos Rep; 2021 Jun; 19(3):271-277. PubMed ID: 33970403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population Pharmacokinetics and Pharmacodynamics of Burosumab in Adult and Pediatric Patients With X-linked Hypophosphatemia.
    Lee SK; Gosselin NH; Taylor J; Roberts MS; McKeever K; Shi J
    J Clin Pharmacol; 2022 Jan; 62(1):87-98. PubMed ID: 34352114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia.
    Linglart A; Imel EA; Whyte MP; Portale AA; Högler W; Boot AM; Padidela R; Van't Hoff W; Gottesman GS; Chen A; Skrinar A; Scott Roberts M; Carpenter TO
    J Clin Endocrinol Metab; 2022 Feb; 107(3):813-824. PubMed ID: 34636899
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Rickets/Osteomalacia. Anti-FGF23 antibody therapy in patients with FGF23-related hypophosphatemic rickets and osteomalacia.].
    Kinoshita Y
    Clin Calcium; 2018; 28(10):1373-1379. PubMed ID: 30269120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Method-specific differences in plasma fibroblast growth factor 23 measurement using four commercial ELISAs.
    Smith ER; McMahon LP; Holt SG
    Clin Chem Lab Med; 2013 Oct; 51(10):1971-81. PubMed ID: 23729624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Burosumab Therapy for X-Linked Hypophosphatemia and Therapeutic Implications for CKD.
    Perwad F; Portale AA
    Clin J Am Soc Nephrol; 2019 Jul; 14(7):1097-1099. PubMed ID: 31171590
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinical practice guidelines for paediatric X-linked hypophosphataemia in the era of burosumab.
    Sandy JL; Simm PJ; Biggin A; Rodda CP; Wall CL; Siafarikas A; Munns CF
    J Paediatr Child Health; 2022 May; 58(5):762-768. PubMed ID: 35426466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improvement in the mobility of a patient with fibroblast growth factor 23-related hypophosphatemic osteomalacia and decompensated liver cirrhosis in response to burosumab: a case report.
    Toi N; Imanishi Y; Nagata Y; Kurajoh M; Morioka T; Shoji T; Shinto Y; Emoto M
    Endocr J; 2023 Apr; 70(4):419-426. PubMed ID: 36575021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period.
    Portale AA; Carpenter TO; Brandi ML; Briot K; Cheong HI; Cohen-Solal M; Crowley R; Jan De Beur S; Eastell R; Imanishi Y; Imel EA; Ing S; Ito N; Javaid M; Kamenicky P; Keen R; Kubota T; Lachmann R; Perwad F; Pitukcheewanont P; Ralston SH; Takeuchi Y; Tanaka H; Weber TJ; Yoo HW; Zhang L; Theodore-Oklota C; Mealiffe M; San Martin J; Insogna K
    Calcif Tissue Int; 2019 Sep; 105(3):271-284. PubMed ID: 31165191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment.
    Kinoshita Y; Fukumoto S
    Endocr Rev; 2018 Jun; 39(3):274-291. PubMed ID: 29381780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changes of the lower limb deformity in children with FGF23-related hypophosphatemic rickets treated with Burosumab: a single-center prospective study.
    Sawamura K; Hamajima T; Izawa M; Kaneko H; Kitamura A; Kitoh H
    J Pediatr Orthop B; 2024 Jan; 33(1):90-96. PubMed ID: 36728857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A case report to assess the safety and efficacy of Burosumab, an investigational antibody to FGF23, in a single pediatric patient with Epidermal Nevus Syndrome and associated hypophosphatemic rickets.
    Huynh C; Gillis A; Fazendin J; Abdullatif H
    Bone Rep; 2022 Dec; 17():101605. PubMed ID: 35899095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. X-linked hypophosphatemia and burosumab: Practical clinical points from the French experience.
    Bacchetta J; Rothenbuhler A; Gueorguieva I; Kamenicky P; Salles JP; Briot K; Linglart A
    Joint Bone Spine; 2021 Oct; 88(5):105208. PubMed ID: 34102329
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined treatment by burosumab and a calcimimetic can ameliorate hypophosphatemia due to excessive actions of FGF23 and PTH in adult XLH with tertiary hyperparathyroidism: A case report.
    Takashi Y; Toyokawa K; Oda N; Muta Y; Yokomizo H; Fukumoto S; Kawanami D
    Front Endocrinol (Lausanne); 2022; 13():1004624. PubMed ID: 36531500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Iron and fibroblast growth factor 23 in X-linked hypophosphatemia.
    Imel EA; Gray AK; Padgett LR; Econs MJ
    Bone; 2014 Mar; 60():87-92. PubMed ID: 24325979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Burosumab treatment for fibrous dysplasia.
    Gladding A; Szymczuk V; Auble BA; Boyce AM
    Bone; 2021 Sep; 150():116004. PubMed ID: 33984553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world effectiveness of burosumab in children with X-linked hypophosphatemic rickets.
    Paloian NJ; Nemeth B; Sharafinski M; Modaff P; Steiner RD
    Pediatr Nephrol; 2022 Nov; 37(11):2667-2677. PubMed ID: 35211790
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Favorable effects of burosumab on tumor-induced osteomalacia caused by an undetectable tumor: A case report.
    Oe Y; Kameda H; Nomoto H; Sakamoto K; Soyama T; Cho KY; Nakamura A; Iwasaki K; Abo D; Kudo K; Miyoshi H; Atsumi T
    Medicine (Baltimore); 2021 Nov; 100(46):e27895. PubMed ID: 34797338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Switching from conventional therapy to burosumab injection has the potential to prevent nephrocalcinosis in patients with X-linked hypophosphatemic rickets.
    Harada D; Ueyama K; Oriyama K; Ishiura Y; Kashiwagi H; Yamada H; Seino Y
    J Pediatr Endocrinol Metab; 2021 Jun; 34(6):791-798. PubMed ID: 33837680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.